Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Hemodynamic effects of a novel sodium channel activator in dogs with chronic heart failure
Autore:
Tanimura, M; Mishima, T; Steinberg, MI; Borzak, S; Goldstein, S; Sabbah, HN;
Indirizzi:
Henry Ford Hosp, Dept Med, Div Cardiovasc Med, Detroit, MI 48202 USA HenryFord Hosp Detroit MI USA 48202 ardiovasc Med, Detroit, MI 48202 USA Vasc Inst, Detroit, MI USA Vasc Inst Detroit MI USAVasc Inst, Detroit, MI USA Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA Lilly Corp CtrIndianapolis IN USA 46285 Labs, Indianapolis, IN 46285 USA
Titolo Testata:
CARDIOVASCULAR DRUGS AND THERAPY
fascicolo: 1, volume: 14, anno: 2000,
pagine: 77 - 82
SICI:
0920-3206(200002)14:1<77:HEOANS>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
FAILING HUMAN MYOCARDIUM; GUINEA-PIG; PHOSPHODIESTERASE INHIBITORS; NA+-CA2+ EXCHANGER; INOTROPIC ACTIONS; CANINE MODEL; DPI 201-106; BDF-9148; DPI-201-106; CALCIUM;
Keywords:
congestive heart failure; sodium channel; ventricular function; inotropic agents; animal models;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Sabbah, HN Henry Ford Hosp, Dept Med, Div Cardiovasc Med, 2799 W Grand Blvd, Detroit,MI 48202 USA Henry Ford Hosp 2799 W Grand Blvd Detroit MI USA 48202 8202 USA
Citazione:
M. Tanimura et al., "Hemodynamic effects of a novel sodium channel activator in dogs with chronic heart failure", CARDIO DRUG, 14(1), 2000, pp. 77-82

Abstract

The use of positive inotropic agents, such as sympathomimetics and phosphodiesterase inhibitors, in heart failure (HF) is limited by proarrhythmic and positive chronotropic effects. In the present study, we compared the hemodynamic effects of intravenous LY366634 (LY), a Na+ channel enhancer, with dobutamine (DOB), in eight dogs with HF produced by intracoronary microembolizations. We also determined whether intravenous LY has synergistic effects when combined with digoxin. After baseline measurements, infusion of DOB was initiated at a dose of 2 mu g/kg/min and increased until an increase ofheart rate (HR) > 30% of baseline or ventricular arrhythmias developed. Once hemodynamics returned to baseline, LY was infused at a dose of 2 mu g/kg/min and increased until the LV fractional area of shortening (FAS), determined echocardiographically, reached a similar level as with DOB. Both drugsincreased FAS equivalently compared to baseline (DOB, 24 +/- 3 to 47 +/- 2; LY, 27 +/- 2 to 46 +/- 2%). DOB increased HR from 78 +/- 4 min(-1) at baseline to 107 +/- 7 min(-1) at maximal dose (p < 0.05) and provoked serious arrhythmias in one dog. In contrast, LY infusion did not increase HR (82 +/- 7 vs. 80 +/- 8 min(-1)) or elicit arrhythmias. After 1 week of oral digoxin, dogs were infused again with LY. A lower dose of LY was needed to achieve the same increase in FAS compared to LY alone, but this was not statistically significant. The combination of LY with digoxin did not increase HR or evoke arrhythmias. We conclude that in dogs with HF, intravenous LY improves LV function to the same extent as DOB without increasing HR or evoking ventricular arrhythmias. The combination of LY with digoxin elicits a safe positive inotropic response.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 23:59:34